Sirna Therapeutics Newswire

Sirna Therapeutics Newswire

Comprehensive Real-Time News Feed for Sirna Therapeutics.

Results 1 - 20 of 564 in Sirna Therapeutics

  1. Tobam Has $21.42 Million Holdings in Alnylam Pharmaceuticals, Inc.Read the original story w/Photo

    Wednesday Nov 14 | AmericanBankingNews.com

    Tobam cut its stake in shares of Alnylam Pharmaceuticals, Inc. by 14.9% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 244,781 shares of the biopharmaceutical company's stock after selling 42,933 shares during the period.

    Comment?

  2. Broadfin Capital, LLC Buys NanoString Technologies Inc, Xenon Pharmaceuticals Inc, La Jolla ...Read the original story w/Photo

    Wednesday Nov 14 | GuruFocus.com

    New York, NY, based Investment company Broadfin Capital, LLC buys NanoString Technologies Inc, Xenon Pharmaceuticals Inc, La Jolla Pharmaceutical Co, Pacific Biosciences of California Inc, ADMA Biologics Inc, Intersect ENT Inc, AngioDynamics Inc, Idera Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, Tesaro Inc, sells Mirati Therapeutics Inc, Endo International PLC, Exact Sciences Corp, Horizon Pharma PLC, Dentsply Sirona Inc during the 3-months ended 2018-09-30, according to the most recent filings of the investment company, Broadfin Capital, LLC. As of 2018-09-30, Broadfin Capital, LLC owns 49 stocks with a total value of $676 million. These are the details of the buys and sells.

    Comment?

  3. Candriam Luxembourg S.C.A. Has $20.24 Million Position in Alnylam Pharmaceuticals, Inc.Read the original story w/Photo

    Tuesday Nov 13 | IntersportsWire

    Candriam Luxembourg S.C.A. lifted its position in Alnylam Pharmaceuticals, Inc. by 94.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 231,210 shares of the biopharmaceutical company's stock after purchasing an additional 112,500 shares during the quarter.

    Comment?

  4. Alnylam Pharmaceuticals (ALNY) Receives Media Impact Rating of -2.50Read the original story w/Photo

    Sunday Nov 11 | AmericanBankingNews.com

    Press coverage about Alnylam Pharmaceuticals has been trending negative recently, according to InfoTrie. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time.

    Comment?

  5. Alnylam Pharmaceuticals (ALNY) Earns Daily Media Impact Score of -2.50Read the original story w/Photo

    Sunday Nov 11 | IntersportsWire

    News coverage about Alnylam Pharmaceuticals has been trending negative this week, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources.

    Comment?

  6. Metabolic Syndrome Market Is Expected to Reach 36700 Million US$ by 2025Read the original story w/Photo

    Saturday Nov 10 | SBWire

    This report focuses on the global Metabolic Syndrome status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Metabolic Syndrome development in United States, Europe and China.Metabolic syndrome is a cluster of conditions - increased blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol or triglyceride levels - that occur together, increasing your risk of heart disease, stroke and diabetes.

    Comment?

  7. Alnylam Pharmaceuticals' (ALNY) "Buy" Rating Reiterated at Cantor FitzgeraldRead the original story w/Photo

    Friday Nov 9 | IntersportsWire

    ". We are reiterating our Overweight rating and $135 price target. We believe that early trends from the launch are in line with our expectations.

    Comment?

  8. Alnylam Pharmaceuticals (ALNY) Hits New 52-Week Low at $70.43Read the original story w/Photo

    Friday Nov 9 | IntersportsWire

    Shares of Alnylam Pharmaceuticals, Inc. reached a new 52-week low during trading on Friday . The stock traded as low as $70.43 and last traded at $72.54, with a volume of 36727 shares traded.

    Comment?

  9. Alnylam Pharmaceuticals, Inc. (ALNY) Position Boosted by Aperio Group LLCRead the original story w/Photo

    Friday Nov 9 | IntersportsWire

    Aperio Group LLC lifted its stake in Alnylam Pharmaceuticals, Inc. by 13.0% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 23,407 shares of the biopharmaceutical company's stock after purchasing an additional 2,695 shares during the quarter.

    Comment?

  10. Alnylam Pharmaceuticals, Inc. (ALNY) Receives Consensus...Read the original story w/Photo

    Thursday Nov 8 | Daily Political

    Alnylam Pharmaceuticals, Inc. has been assigned a consensus rating of "Buy" from the twenty-one research firms that are presently covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and fifteen have assigned a buy rating to the company.

    Comment?

  11. Alnylam: 3Q Earnings SnapshotRead the original story w/Photo

    Wednesday Nov 7 | Greenwich Citizen

    The Cambridge, Massachusetts-based company said it had a loss of $2.43 per share. Losses, adjusted for stock option expense, came to $1.56 per share.

    Comment?

  12. Alnylam Pharmaceuticals (ALNY) Posts Quarterly Earnings Results, Misses Estimates By $0.40 EPSRead the original story w/Photo

    Wednesday Nov 7 | AmericanBankingNews.com

    Alnylam Pharmaceuticals announced its quarterly earnings data on Wednesday. The biopharmaceutical company reported earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of by , MarketWatch Earnings reports.

    Comment?

  13. Alnylam shares take a hit amid sluggish sales of first drugRead the original story

    Wednesday Nov 7 | Business Journal

    Shares of Alnylam Pharmaceuticals fell Wednesday after the Cambridge biotech reported a slow uptake of its first FDA-approved drug, an expensive, first-of-its-kind treatment for a rare disease that is difficult to diagnose.

    Comment?

  14. Class Action Alert: Brower Piven Notifies Investors of Class Action...Read the original story

    Wednesday Nov 7 | Law.com

    CLASS ACTION ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Significant Losses From Investment In Alnylam Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline STEVENSON, Md., -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Alnylam Pharmaceuticals, Inc. securities during the period between February 15, 2018 and September 12, 2018, inclusive . Investors who wish to become proactively involved in the litigation have until November 26, 2018 to seek appointment as lead plaintiff.

    Comment?

  15. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story w/Photo

    Wednesday Nov 7 | Business Wire

    Our Company reported Basic Earnings per Shar... )--Radient Technologies Inc. and Grupo Natac S.L. are pleased to announce the formal launch of their joint venture Natac Solution... )--Security Alarms & Co., developpeur suisse de securite domestique intelligente a annonce aujourd'hui avoir choisi les services IoT de Sierra Wireless --Brought to life through delicate art, detailed animation and an elegant original score, ethereal indie game GRIS comes to the Nintendo Switch system on Dec. 13. The... )--CALIENT said its S320 is part of SCinet, the "world's fastest network" adding connectivity flexibility with no impact on network throughput or latency )--Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter 2018 a... )--The "Biosimulation Market Size, Share & Trend Analysis Report By Product , By ... (more)

    Comment?

  16. Alnylam Pharmaceuticals (ALNY) Upgraded by BidaskClub to SellRead the original story w/Photo

    Tuesday Nov 6 | IntersportsWire

    Several other equities analysts also recently issued reports on ALNY. ValuEngine upgraded shares of Alnylam Pharmaceuticals from a buy rating to a strong-buy rating in a report on Wednesday, July 11th.

    Comment?

  17. Class Action Update for Opk, Abbv and Alny: Levi & Korsinsky, LLP...Read the original story

    Tuesday Nov 6 | World News Report

    Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided.

    Comment?

  18. Alnylam Pharmaceuticals (ALNY) Upgraded by BidaskClub to "Sell"Read the original story w/Photo

    Monday Nov 5 | Daily Political

    A number of other research analysts also recently issued reports on the stock. Cantor Fitzgerald started coverage on shares of Alnylam Pharmaceuticals in a research report on Monday, October 1st.

    Comment?

  19. Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for...Read the original story w/Photo

    Monday Nov 5 | GlobeNewswire

    The law firm of Kessler Topaz Meltzer & Check, LLP reminds Alnylam Pharmaceuticals, Inc. investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Southern District of New York against Alnylam on behalf of purchasers of Alnylam securities between February 15, 2018 and September 12, 2018 , inclusive . , seek to be appointed as a lead plaintiff representative of the class.

    Comment?

  20. Class Action Update for Alny and CPB: Levi & Korsinsky, LLP Reminds...Read the original story

    Wednesday Oct 31 | World News Report

    Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided.

    Comment?